This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F20.1 (Hebephrenic schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduction for 5 years after registration) |
| B. Synonyms | Hebephrenic schizophrenia; Disorganized schizophrenia; Hebephrenia |
| C. Adult onset | Likelihood of first onset in adulthood: Low — Hebephrenic schizophrenia has the earliest age of onset among the schizophrenia subtypes, with onset mainly in adolescence and early adulthood (ages 15-25). First onset after age 25 is rare, and for onset after early adulthood, other subtypes or organic causes should be considered first. |
| 1. History | 1871: Hecker describes hebephrenia → included as a subtype of Kraepelin's dementia praecox → classified as ICD-10 F20.1 → subtype abolished in DSM-5, corresponding to the disorganized type. |
| 2. Causes | High genetic load, early neurodevelopmental disturbance, and abnormal prefrontal connectivity are prominent; as a negative-symptom-dominant type, glutamate and GABA abnormalities are relatively more important than dopamine. |
| 3. Genetics | A subtype with prominent negative symptoms and cognitive deficits; associations reported with variants of prefrontal function-related genes (COMT Val158Met, DTNBP1, NRG1); tendency toward high genetic load. |
| 4. General epidemiology | A relatively rare subtype, about 10-15% of all schizophrenia; characterized by early onset at ages 15-25; slightly more common in men; a poor-prognosis group. |
| 5. Pathophysiology | Prefrontal-limbic disconnection; working memory impairment and negative symptoms due to reduced DLPFC function; overactivity and dysregulation of the default mode network (DMN). |
| 6. Symptoms | Disorganized speech (derailment, incoherence), disorganized behavior, and inappropriate or blunted affect are the three core symptoms; accompanied by unsystematized delusions and hallucinations; self-care and social function decline rapidly. |
| 7. Signs | Marked thought derailment and loosening of associations during interview; inappropriate laughter and bizarre facial expressions; poor self-care; high PANSS negative and general psychopathology subscale scores. |
| 8. Screening | Adolescent mental health screening (K-YSR, CBCL), thought disorder indices (TDI), early application of the SANS (negative symptom scale); when function declines, use school and community early detection systems. |
| 9. Diagnosis | ICD-10 F20.1 criteria: disorganized speech, behavior, and affect dominate the clinical picture, and any delusions or hallucinations are fragmentary; exclusion of organic causes (frontal lobe lesion, autoimmune encephalitis) is essential. |
| 10. Treatment | Clozapine is relatively effective for negative and cognitive symptoms; cognitive remediation, social skills training; prevention of regression with structured day programs; maintain adherence with LAI. |
| 11. Prognosis | The worst prognosis among schizophrenia subtypes; rapid progression of negative symptoms, cognitive decline, and decline in social function are prominent; high likelihood of long-term hospitalization and dependent living. |
| 12. Prevention | Early management of neurodevelopmental risk factors; adolescent mental health early detection programs; rapid shortening of DUP; prevention of regression with structured social function maintenance programs. |
| 13. References | Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022 … and 9 other articles |
The history of hebephrenic schizophrenia (hebephrenia) begins with the taxonomic efforts of German psychiatry in the late 19th century. In 1871, the German Ewald Hecker, under the guidance of his teacher Kahlbaum, described a mental illness that begins in adolescence and shows rapid personality disintegration and devastation, and named it 'Hebephrenie (hebephrenia)' after Hebe, the goddess of youth. Hecker described thought disorder, inappropriate affect (Unsinn and Blödsinn, i.e., silliness and dullness), bizarre behavior, and rapid personality devastation as features of this illness.
In 1896, Emil Kraepelin included Hecker's hebephrenia, together with the paranoid and catatonic forms, as one of the three subtypes of 'dementia praecox.' Kraepelin emphasized the clinical characteristics of the hebephrenic type: the earliest age of onset (adolescence), the course that progresses most rapidly to devastation, and the worst prognosis. In 1911, when Eugen Bleuler proposed the name 'schizophrenia,' he described the loosening of associations and affective abnormalities of the hebephrenic type as best showing the basic symptoms of schizophrenia.
As international classification systems developed from the mid-20th century, hebephrenic schizophrenia was included in both the ICD and the DSM. It was kept as a separate subtype in ICD-9 (1978) and DSM-III (1980), but DSM-III adopted the name 'Disorganized type' and used a functional descriptor in place of hebephrenic. ICD-10 (1992) retained the classification as F20.1 Hebephrenic schizophrenia, and DSM-IV (1994) retained the Disorganized type.
In 2013, DSM-5 abolished all schizophrenia subtypes, and the hebephrenic/disorganized type was also removed as an independent diagnostic category. DSM-5 merged schizophrenia into a single diagnosis and shifted to assessment by symptom dimensions. The reasons are the unclear boundaries between subtypes, longitudinal instability (the phenomenon of a patient's subtype changing over the course), and the absence of evidence for subtype-specific treatment. In contrast, ICD-10 and ICD-11 still recognize the hebephrenic/disorganized type as a separate clinical category, and in Korean clinical practice ICD-10 F20.1 is used as the current insurance code. ICD-11 (2022) introduces symptom specifiers to express the characteristics of subtypes while moving toward unifying the official code.
In Korea, since the official term for schizophrenia changed in 2012 from 'jeongsinbunyeolbyeong' to 'johyeonbyeong', the older 'hebephrenic jeongsinbunyeoljeung' is written as 'hebephrenic schizophrenia' or 'disorganized schizophrenia'. In Korean psychiatric clinical settings, hebephrenic schizophrenia is regarded as a severe mental illness requiring an intensive multidisciplinary approach because of its early onset, high negative symptom burden, and treatment difficulty.
The causes of hebephrenic schizophrenia are understood by the vulnerability-stress model shared with schizophrenia as a whole, but it is characterized by more prominent neurodevelopmental abnormalities and genetic load.
Genetic factors: Hebephrenic schizophrenia is reported to have the highest genetic load among the schizophrenia subtypes. There is clinical observation that familial clustering is stronger than in the paranoid type, suggesting that genetic predisposition plays a larger role in onset. Most schizophrenia risk loci identified in large GWAS also apply to the hebephrenic type, and in particular variants of COMT, DTNBP1, NRG1, and others related to prefrontal function are associated with negative symptoms and cognitive deficits.
Neurodevelopmental abnormalities: In patients with hebephrenic schizophrenia, evidence of prenatal and early neurodevelopmental disorder is relatively clear. A model has been proposed in which perinatal complications, neuronal migration defects, and abnormal early synaptic pruning lead to impaired prefrontal connectivity. Abnormalities in social, cognitive, and motor development before school age are reported more frequently in patients with the hebephrenic type.
Neurochemical factors: There is a view that in the hebephrenic type, glutamate and GABA system abnormalities are more prominent than dopamine, unlike the paranoid type. Decreased dopamine in the prefrontal cortex (PFC) and reduced function of GABA interneurons (especially PV-positive fast-spiking interneurons) are studied as core mechanisms of negative symptoms and cognitive deficits. Decreased cortical inhibitory neuronal activity due to reduced NMDA receptor function contributes to thought disorder and affect dysregulation.
Environmental factors: The relative contribution of environmental factors in hebephrenic schizophrenia is thought to be smaller than in the paranoid type, but school maladjustment, social isolation, and adolescent traumatic experiences associated with early onset act as triggering factors. When psychoactive substances such as cannabis are used in adolescence, they may cause hebephrenic-like symptoms or bring forward onset.
The genetics of hebephrenic schizophrenia is understood in the context of genetic studies of schizophrenia as a whole, but subtype-specific genetic studies are limited by sample size. The following are the main genetic findings related to hebephrenic characteristics.
Genes related to prefrontal function: The COMT (Catechol-O-Methyltransferase) Val158Met polymorphism is associated with prefrontal cortical dopamine metabolism, and the Met/Met genotype is associated with prefrontal activity and working memory performance. Heterozygous variants of DTNBP1 (dysbindin) have been reported in several cohorts to be associated with negative symptoms and cognitive deficits. NRG1 (Neuregulin 1) variants are related to dysregulation of glutamate and dopamine signaling and are involved in the mechanism of disorganization symptoms in the hebephrenic type.
Genes related to synaptic pruning: In 2016, Sekar et al. (Nature) reported that structural variation of the complement C4 gene is associated with excessive synaptic pruning. Excessive synaptic pruning in adolescence is a mechanism consistent with the early onset and rapid devastation process prominent in the hebephrenic type. This draws attention as an important clue that neurobiologically explains why the hebephrenic type begins in adolescence.
Copy number variation (CNV): Various CNVs, including 22q11.2 deletion, increase risk for schizophrenia overall, and CNVs associated with neurodevelopmental abnormalities and early onset are presumed to be relevant in the hebephrenic type as well. There are reports that cognitive deficits and negative symptoms are prominent in carriers of CNVs such as 1q21.1 deletion and 15q11.2 deletion.
Epigenetics: There are reports that increased prefrontal BDNF (Brain-Derived Neurotrophic Factor) promoter methylation and decreased BDNF expression are observed in patients with hebephrenic schizophrenia. Decreased BDNF is associated with reduced synaptic plasticity, reduced neuronal survival, and cognitive decline. These epigenetic abnormalities are understood as a mechanism mediating the interaction between environmental stress and genetic predisposition.
Hebephrenic schizophrenia is a relatively rare subtype, accounting for about 10-15% of all schizophrenia diagnoses. It is classified under ICD-10 code F20.1, and since the abolition of subtypes in DSM-5, separate prevalence statistics have been decreasing in the West, but it is still identified as an independent category in Korea and European countries that use ICD-10.
Age of onset: Hebephrenic schizophrenia has the earliest age of onset among the schizophrenia subtypes. Most cases begin at ages 15-25, and onset in the early teens is reported in some. Early onset reflects deeper involvement of neurodevelopmental abnormalities and causes problems such as dropping out of school, decline in social function, and diagnostic delay. Because functional impairment accumulates the longer the diagnostic delay, early detection in adolescent mental health services is important.
Sex differences: Slightly more common in men, and in women as well it tends to begin in adolescence to early adulthood. Overall, the sex difference seen in schizophrenia (earlier onset in men) is more pronounced in the hebephrenic type.
Prognosis and epidemiologic characteristics: The hebephrenic type has the poorest long-term prognosis among schizophrenia subtypes, and is the group with the highest long-term hospitalization rate and functional dependence. Early onset, high negative symptom burden, cognitive deficits, and lack of social skills act in combination, making independent living and job retention difficult. Long-term follow-up studies in developed countries report that about 60-70% of patients with the hebephrenic type have severe functional impairment after 10 years.
Epidemiology in Korea: In Korea, F20.1 hebephrenic schizophrenia accounts for a relatively small proportion of all patients treated for schizophrenia, but its severity and resource use are high, placing a heavy burden on mental health services. The proportion of patients with hebephrenic schizophrenia is reported to be high in Korean mental health welfare centers and psychiatric rehabilitation facilities. Registration for Special Copayment Reduction (V161) provides the benefit of reduced outpatient and inpatient costs.
The core pathophysiology of hebephrenic schizophrenia is summarized as abnormal prefrontal-limbic connectivity and abnormal synaptic development and pruning.
Reduced prefrontal function: Reduced function of the dorsolateral prefrontal cortex (DLPFC) is the direct cause of impaired working memory, cognitive flexibility, and executive function. In fMRI studies, patients with hebephrenic schizophrenia show markedly reduced DLPFC activation during cognitive tasks, which correlates strongly with negative symptoms (avolition, alogia). Decreased D1 receptors and decreased dopamine in the PFC are the neurochemical basis of this reduced function.
Abnormal synaptic pruning: In normal adolescence, excess synapses are pruned to form efficient neural networks, but a hypothesis is strongly proposed that in hebephrenic schizophrenia this process proceeds abnormally excessively or malfunctions. Excessive pruning due to C4 complement gene overexpression sharply reduces prefrontal synaptic density and explains the rapidly devastating course of the hebephrenic type. This is the key mechanism explaining why the hebephrenic type begins in adolescence and progresses rapidly.
Default mode network abnormality: In patients with hebephrenic schizophrenia, abnormal overactivity of the Default Mode Network (DMN) and failure of appropriate deactivation during engagement in external tasks are reported. This is an imbalance between internal self-referential thought and responsiveness to the external environment, understood as the neuroscientific basis of disorganized speech and inappropriate emotional expression.
GABA interneuron abnormality: A decrease in parvalbumin (PV)-positive fast-spiking GABAergic interneurons in the prefrontal cortex is consistently observed in postmortem brain studies of hebephrenic schizophrenia. These interneurons coordinate cortical gamma oscillations (40 Hz), and their decrease leads to abnormal gamma oscillations, reduced information processing efficiency, and disorganized thought and speech. This abnormality is understood to be induced secondarily by reduced NMDA receptor function.
The clinical symptoms of hebephrenic schizophrenia are centered on disorganization of thought, speech, behavior, and affect, and any delusions and hallucinations are fragmentary and unsystematized.
Disorganized speech: Derailment, loosening of associations, incoherence, clang association (linking meaningless words), and neologism are prominent. During conversation the topic repeatedly drifts, sentences do not finish, or there is a sudden switch to completely unrelated content. When thought disorder is severe, speech progresses to the level of being almost incomprehensible (word salad).
Disorganized behavior: Characterized by purposeless repetitive behavior, bizarre gestures, inappropriate laughter, and rapid decline in self-care (hygiene, eating, dress). The ability to perform daily tasks is markedly impaired, making independent living impossible. At times infantile regressive behavior (giggling, laughing alone, silly behavior) appears.
Affective disturbance: Both affective blunting and incongruous affect (emotional expression that does not fit the situation) appear. Laughing while talking about serious matters, being expressionless in joyful situations, and suddenly bursting into laughter for no reason are characteristic. The unpredictability of emotional responses makes interpersonal relationships even more difficult.
Delusions and hallucinations: Delusions and hallucinations may accompany, but unlike the paranoid type they are not a systematized delusional system; the content is fragmentary and changeable. Even when auditory hallucinations are present, the response to them is inconsistent or off-target. The content of delusions changes frequently and lacks logical consistency.
Negative symptoms: Avolition, anhedonia, alogia, affective flattening, and social withdrawal are prominent, and the negative symptom burden is much greater than in the paranoid type. Negative symptoms respond slowly to treatment and carry a high risk of chronicity.
The clinical signs of hebephrenic schizophrenia show a pattern distinctly different from the paranoid type on mental status examination. Marked abnormalities in speech, behavior, affect, and appearance are characteristic.
Observation of appearance and behavior: Appearance and self-care are markedly deteriorated. Untidy clothing, poor hygiene, tangled hair, and inappropriate attire (not suited to the season or situation) are observed. Bizarre, purposeless behavior (aimless wandering, repetitive movements, self-stimulating behavior) appears. Eye contact with the interviewer is irregular, and sudden laughter or bizarre facial expressions recur.
Assessment of speech and thought: During interview, thought derailment, loosening of associations, and incoherence are marked, making communication difficult. Answers drift off-topic unrelated to the question or include neologisms and meaningless word combinations. Quantitative assessment is possible with the Thought Disorder Index (TDI) or the Thought, Language, and Communication Scale (TLC).
Emotional state: Affective blunting and incongruous affect coexist, with unpredictable emotional changes such as being almost expressionless and then suddenly bursting into laughter. Differentiation from mood episodes (mania, depression) is needed, but the absence of mood symptoms in the foreground is characteristic of the hebephrenic type.
Cognitive function: Neuropsychological testing confirms marked deficits in working memory, processing speed, executive function, and verbal fluency. On the MCCB (MATRICS Consensus Cognitive Battery), patients with the hebephrenic type show a generally lower cognitive profile than other subtypes. Cognitive impairment has a limited response to treatment and directly affects long-term functional prognosis.
Early screening for hebephrenic schizophrenia focuses on capturing functional decline and thought and speech abnormalities in adolescents and young adults.
Adolescent mental health screening tools: On adolescent behavior problem screening tools such as the K-YSR (Korean Youth Self-Report) and CBCL (Child Behavior Checklist), an elevated Thought Problems subscale score may reflect prodromal signs of hebephrenic schizophrenia. Sudden decline in school performance, social withdrawal, and bizarre speech and behavior are early detection signals for teachers and school counselors.
Assessment of thought disorder: The clinician-administered Thought Disorder Index (TDI), the thought disorder indices of the Rorschach test, and the conceptual disorganization item of the PANSS general psychopathology subscale are used to assess hebephrenic symptoms. Natural language processing (NLP) technology that quantifies abnormal speech patterns in speech sample analysis is being used at the research stage.
Screening for negative symptoms: Negative-symptom-specific instruments such as the SANS (Scale for the Assessment of Negative Symptoms) and CAINS (Clinical Assessment Interview for Negative Symptoms) are useful for early detection of negative symptoms, the core symptoms of the hebephrenic type. Negative symptoms must be distinguished from depression, social anxiety disorder, and the like, and comprehensive assessment is done in the context of functional decline.
Community- and school-based early detection: Screening systems in adolescent mental health welfare centers, school counseling systems, and university mental health services contribute to shortening the DUP of hebephrenic schizophrenia. Korean mental health early intervention programs (Maeum-ieum, Narae Center, etc.) play this role.
Diagnosis of hebephrenic schizophrenia proceeds as a stepwise process: confirming, according to ICD-10 F20.1 criteria, that it is schizophrenia in which disorganized speech, behavior, and affect dominate the clinical picture, and excluding organic causes and other mental disorders.
ICD-10 F20.1 diagnostic criteria: Diagnosed when the general criteria for schizophrenia (F20) are met and ① marked affective blunting or inappropriate affect, ② disorganized thought or incoherent speech, and ③ purposeless, disorganized behavior dominate the clinical picture. Any delusions or hallucinations must be fragmentary and unsystematized. A minimum of 2-3 months of clinical observation is needed for diagnosis.
Differential diagnosis: ① Autism spectrum disorder (ASD): social communication abnormalities and repetitive behavior are present, but appear developmentally from infancy. ② Organic frontal lobe syndrome: disorganization symptoms due to frontal lobe lesions (tumor, trauma, vascular) are excluded by brain imaging. ③ Autoimmune encephalitis (NMDAR antibody, LGI1 antibody, etc.): CSF antibody testing when acute or subacute onset, seizures, altered consciousness, or autonomic abnormalities accompany. ④ Manic episode (mood-driven): when mood episodes are in the foreground, differentiate from schizoaffective disorder or bipolar disorder. ⑤ Substance-induced psychosis: acute psychosis caused by substance use such as cannabis or methamphetamine is differentiated by resolution of symptoms after withdrawal.
Essential tests: Blood tests (complete blood count, metabolic panel, thyroid function, autoimmune antibodies, syphilis, HIV), urine drug screen, brain MRI (exclusion of frontal lobe lesions), EEG (exclusion of temporal lobe epilepsy), neuropsychological testing (assessment of baseline cognitive function).
Treatment of hebephrenic schizophrenia is based on antipsychotic medication, but an integrated approach that takes into account the refractory nature of disorganization and negative symptoms is essential.
Antipsychotic medication: Second-generation antipsychotics are first-line treatment, but their effect on negative symptoms and cognitive deficits is limited. Olanzapine is reported to be relatively effective for negative symptoms, and risperidone, quetiapine, and others are used. Clozapine shows the best effect in treatment-resistant hebephrenic schizophrenia that has not responded to two or more drugs, and there is evidence that it is relatively favorable for improving negative symptoms and cognitive function. Regular blood monitoring (risk of agranulocytosis) is essential when using clozapine. LAI (long-acting injectables) are particularly useful for maintaining adherence.
Cognitive remediation: Cognitive Enhancement Therapy (CET), Cognitive Remediation Therapy (CRT), and computer-based cognitive training play an adjunctive role in improving cognitive deficits in hebephrenic schizophrenia. The Social Cognition and Interaction Training (SCIT) program is used to improve social skills deficits.
Structured day programs: Structured programs at day hospitals and psychiatric rehabilitation centers (daily living training, occupational therapy, social skills training) are key to preventing functional regression and maintaining self-care ability. Cognitive behavioral therapy is applied centered on functional goals rather than individual symptoms.
Family support and community treatment: Through family psychoeducation, caregivers are helped to understand the characteristics of hebephrenic symptoms (for example, negative symptoms are not laziness) and respond appropriately. Intensive community treatment through an ACT (Assertive Community Treatment) team is effective in reducing hospitalization and maintaining community functioning.
Hebephrenic schizophrenia has the worst prognosis among schizophrenia subtypes. Early onset, high negative symptom burden, severe cognitive deficits, and rapid functional devastation act in combination.
Functional outcome: In long-term follow-up studies, about 60-75% of patients with the hebephrenic type have severe functional impairment after 10-20 years, and independent living and employment are often difficult. Functional decline progresses fastest within 2 years after first onset, and then tends to enter a chronic stable phase. Complete remission (symptom resolution + functional recovery) is achieved in only about 10-15%.
Course of cognitive and negative symptoms: Cognitive impairment has a limited response to treatment, and gradual worsening over time is observed in some patients. Negative symptoms respond relatively little to antipsychotic medication and often persist chronically. Combining clozapine and cognitive remediation is the best approach, but the effect size is limited.
Prognostic predictors: Poor prognostic factors include early age of onset, male sex, premorbid functional decline, high negative symptom burden, prolonged DUP, substance use, and treatment nonadherence. A relatively good prognosis is associated with rapid access to treatment, family support, and participation in structured rehabilitation.
Mortality: The suicide risk of patients with hebephrenic schizophrenia is reported to be similar to or slightly lower than the average for schizophrenia overall, but the risk of premature death from physical illness due to poor self-care (malnutrition, infection, accidents) is high. Continuous monitoring of physical health is necessary.
Prevention of hebephrenic schizophrenia focuses on adolescent mental health intervention in view of its early-onset characteristics.
Primary prevention: Prevention of prenatal infection, minimizing perinatal complications, and prevention of childhood trauma contribute to reducing neurodevelopmental risk. Preventing cannabis use in adolescence is important for suppressing early onset.
Secondary prevention — early detection and shortening DUP: Through mental health literacy education in schools and communities, teachers, parents, and peers are helped to recognize prodromal symptoms of hebephrenic schizophrenia (bizarre speech and behavior, social withdrawal, sudden decline in school performance) and connect to professional services. Shortening DUP is the factor with the greatest effect on long-term prognosis. Rapid connection to an adolescent mental health early intervention program (EIP) is key.
Tertiary prevention — preventing regression and maintaining function: Structured daily routine, regular participation in day hospital and rehabilitation, maintenance antipsychotic medication (LAI if possible), cognitive remediation, and family education are the key elements for suppressing functional regression. Physical health (nutrition, hygiene, infection prevention) and management of substance use are also important. Regular assessment of suicide risk and self-harm risk and establishing a safety plan are essential items in follow-up care.
Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.
Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-183. DOI: 10.1038/nature16549. PMID: 26814963.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia. Neurosci Biobehav Rev. 2011;35(3):573-588. DOI: 10.1016/j.neubiorev.2010.07.001. PMID: 20620163.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. DOI: 10.1016/S2215-0366(18)30050-4. PMID: 29909215.
Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677-1687. DOI: 10.1016/S0140-6736(13)62036-X. PMID: 24315522.
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. DOI: 10.1002/wps.20516. PMID: 29745131.
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485. DOI: 10.1176/appi.ajp.2010.10060855. PMID: 21406461.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.